These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
414 related articles for article (PubMed ID: 16831922)
1. Interactive effect of interleukin-6 and prostaglandin E2 on osteoclastogenesis via the OPG/RANKL/RANK system. Liu XH; Kirschenbaum A; Yao S; Levine AC Ann N Y Acad Sci; 2006 Apr; 1068():225-33. PubMed ID: 16831922 [TBL] [Abstract][Full Text] [Related]
2. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system. Liu XH; Kirschenbaum A; Yao S; Levine AC Endocrinology; 2005 Apr; 146(4):1991-8. PubMed ID: 15618359 [TBL] [Abstract][Full Text] [Related]
3. Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption. Aubin JE; Bonnelye E Medscape Womens Health; 2000 Mar; 5(2):5. PubMed ID: 10792853 [TBL] [Abstract][Full Text] [Related]
4. Microrough implant surface topographies increase osteogenesis by reducing osteoclast formation and activity. Lossdörfer S; Schwartz Z; Wang L; Lohmann CH; Turner JD; Wieland M; Cochran DL; Boyan BD J Biomed Mater Res A; 2004 Sep; 70(3):361-9. PubMed ID: 15293309 [TBL] [Abstract][Full Text] [Related]
5. Lipopolysaccharide from Prevotella nigrescens stimulates osteoclastogenesis in cocultures of bone marrow mononuclear cells and primary osteoblasts. Chung YH; Chang EJ; Kim SJ; Kim HH; Kim HM; Lee SB; Ko JS J Periodontal Res; 2006 Aug; 41(4):288-96. PubMed ID: 16827722 [TBL] [Abstract][Full Text] [Related]
6. Alpha-lipoic acid suppresses osteoclastogenesis despite increasing the receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio in human bone marrow stromal cells. Koh JM; Lee YS; Byun CH; Chang EJ; Kim H; Kim YH; Kim HH; Kim GS J Endocrinol; 2005 Jun; 185(3):401-13. PubMed ID: 15930166 [TBL] [Abstract][Full Text] [Related]
7. Prostaglandin E2 induces expression of receptor activator of nuclear factor-kappa B ligand/osteoprotegrin ligand on pre-B cells: implications for accelerated osteoclastogenesis in estrogen deficiency. Kanematsu M; Sato T; Takai H; Watanabe K; Ikeda K; Yamada Y J Bone Miner Res; 2000 Jul; 15(7):1321-9. PubMed ID: 10893680 [TBL] [Abstract][Full Text] [Related]
8. Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption. Aubin JE; Bonnelye E Osteoporos Int; 2000; 11(11):905-13. PubMed ID: 11193242 [TBL] [Abstract][Full Text] [Related]
9. IL-1 alpha stimulates the formation of osteoclast-like cells by increasing M-CSF and PGE2 production and decreasing OPG production by osteoblasts. Tanabe N; Maeno M; Suzuki N; Fujisaki K; Tanaka H; Ogiso B; Ito K Life Sci; 2005 Jun; 77(6):615-26. PubMed ID: 15921993 [TBL] [Abstract][Full Text] [Related]
10. Long chain polyunsaturated fatty acids alter membrane-bound RANK-L expression and osteoprotegerin secretion by MC3T3-E1 osteoblast-like cells. Poulsen RC; Wolber FM; Moughan PJ; Kruger MC Prostaglandins Other Lipid Mediat; 2008 Feb; 85(1-2):42-8. PubMed ID: 18077200 [TBL] [Abstract][Full Text] [Related]
11. Effects of prostaglandin E2 on gene expression in primary osteoblastic cells from prostaglandin receptor knockout mice. Li X; Pilbeam CC; Pan L; Breyer RM; Raisz LG Bone; 2002 Apr; 30(4):567-73. PubMed ID: 11934647 [TBL] [Abstract][Full Text] [Related]
12. TNF receptor type 1 regulates RANK ligand expression by stromal cells and modulates osteoclastogenesis. Abu-Amer Y; Abbas S; Hirayama T J Cell Biochem; 2004 Nov; 93(5):980-9. PubMed ID: 15389885 [TBL] [Abstract][Full Text] [Related]
13. Osteoprotegerin and inflammation. Saidenberg Kermanac'h N; Bessis N; Cohen-Solal M; De Vernejoul MC; Boissier MC Eur Cytokine Netw; 2002; 13(2):144-53. PubMed ID: 12101070 [TBL] [Abstract][Full Text] [Related]
14. Regulation of osteoclastogenesis by gap junction communication. Matemba SF; Lie A; Ransjö M J Cell Biochem; 2006 Oct; 99(2):528-37. PubMed ID: 16639710 [TBL] [Abstract][Full Text] [Related]
15. [Osteoclastogenesis Inhibitory Factor (OCIF) /Osteoprotegerin (OPG) as a new therapeutic agent for osteoporosis]. Mochizuki S; Kiyokawa A; Nagayama Y Clin Calcium; 2005 Jan; 15(1):35-42. PubMed ID: 15632471 [TBL] [Abstract][Full Text] [Related]
16. Mechanical stimulation effects on functional end effectors in osteoblastic MG-63 cells. Saunders MM; Taylor AF; Du C; Zhou Z; Pellegrini VD; Donahue HJ J Biomech; 2006; 39(8):1419-27. PubMed ID: 15953606 [TBL] [Abstract][Full Text] [Related]
17. Effects of polyethylene and TiAlV wear particles on expression of RANK, RANKL and OPG mRNA. Baumann B; Rader CP; Seufert J; Nöth U; Rolf O; Eulert J; Jakob F Acta Orthop Scand; 2004 Jun; 75(3):295-302. PubMed ID: 15260421 [TBL] [Abstract][Full Text] [Related]
18. Effects of arachidonic acid, docosahexaenoic acid, prostaglandin E(2) and parathyroid hormone on osteoprotegerin and RANKL secretion by MC3T3-E1 osteoblast-like cells. Coetzee M; Haag M; Kruger MC J Nutr Biochem; 2007 Jan; 18(1):54-63. PubMed ID: 16650751 [TBL] [Abstract][Full Text] [Related]
19. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Collin-Osdoby P Circ Res; 2004 Nov; 95(11):1046-57. PubMed ID: 15564564 [TBL] [Abstract][Full Text] [Related]
20. Basic fibroblast growth factor induces osteoclast formation by reciprocally regulating the production of osteoclast differentiation factor and osteoclastogenesis inhibitory factor in mouse osteoblastic cells. Nakagawa N; Yasuda H; Yano K; Mochizuki Si; Kobayashi N; Fujimoto H; Shima N; Morinaga T; Chikazu D; Kawaguchi H; Higashio K Biochem Biophys Res Commun; 1999 Nov; 265(1):158-63. PubMed ID: 10548507 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]